Open
寶泰生醫(yī)成立於2019年，公司致力於伴侶動(dòng)物免疫治療藥物的研發(fā)，目標(biāo)是成為亞太地區(qū)寵物疾病免疫治療領(lǐng)先者。寶泰的研發(fā)團(tuán)隊(duì)來自於美國哈佛大學(xué)、哥倫比亞大學(xué)、美國默克公司等，累積數(shù)十年人類藥物開發(fā)經(jīng)驗(yàn)。過去曾完成四項(xiàng)候選藥物由實(shí)驗(yàn)室到美國人體臨床二期的開發(fā)工作。寶泰目前已有全球第一個(gè)廣譜性動(dòng)物癌癥治療產(chǎn)品PT001，準(zhǔn)備進(jìn)入臨床試驗(yàn)。寶泰生目前正在尋求項(xiàng)目/技術(shù)平臺(tái)與全球動(dòng)物藥品企業(yè)的合作機(jī)會(huì)。
the company is committed to the research and development of companion animal immunotherapy drugs with the goal of becoming a leader in pet disease immunotherapy in the Pan-Asia region. Protect Biotech currently has the world's first broad-spectrum animal cancer treatment product PT001, ready to enter clinical trials
the company is committed to the research and development of companion animal immunotherapy drugs with the goal of becoming a leader in pet disease immunotherapy in the Pan-Asia region. Protect Biotech currently has the world's first broad-spectrum animal cancer treatment product PT001, ready to enter clinical trials